Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Hematology
Multispecialty Spotlight
Multi-specialty Spotlight
Questions discussed in this category
Should testing for genetic causes of HLH be performed in all patients with MAS or secondary HLH regardless of the patient's age?
2 Answers available
How do you approach dosing of anakinra in MAS?
1 Answer available
How do you approach diagnosis and treatment of HLH/MAS following CAR T-cell therapy?
How is this entity distinct from other secondary HLH entities?
2 Answers available
What is your approach to treatment of infection-triggered HLH that does not respond to treatment of the underlying infection?
2 Answers available
In the setting of secondary HLH associated with initial diagnosis of lymphoma, would you adjust steroid dose and type to account for differences in HLH and lymphoma treatment protocols?
1 Answer available
What are the best labs to trend improvement in HLH?
1 Answer available
14670
16225
16186
16217
16195
15429
Papers discussed in this category
Pediatric blood & cancer, 2011-01
Rate of decline of ferritin in patients with hemophagocytic lymphohistiocytosis as a prognostic variable for mortality.
Ther Adv Musculoskelet Dis, 2020 Nov 24
Efficacy of high-dose anakinra in refractory macrophage activation syndrome in adult-onset Still's disease: when dosage matters in overcoming secondary therapy resistance.
Related Topics in Hematology
Lung Cancer
Breast Cancer
Head and Neck Cancers
Hematologic Malignancies
Radiation Oncology
Gynecologic Cancers
Palliation
Neuro-Oncology
Gastrointestinal Cancers
Genitourinary Cancers